Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma

By afschroeder • February 2, 2026

Robatel S, Hillen H, Mutisheva I, Müller JC, Wartenberg M, Ma F, Bäriswyl L, Evenepoel J, Scheele CLGJ, Lee DJ, Modlin RL, Kessler U, Nobis M, Z'graggen K, Schenk M. Agonistic GITR treatment enhances antitumor immune responses and suppresses tumor progression in pancreatic ductal adenocarcinoma. J Gastroenterol. 2026 Feb 1. doi: 10.1007/s00535-026-02347-y. Epub ahead of print. PMID: 41620983.

Tags: Dermatology, Harbor UCLA, Immunomodulation, immunotherapy, pancreatic ductal adenocarcinoma, Publications, Transcriptomics, tumor microenvironment

ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

Assan F, Tragin M, Marella S, Lipecka J, Roger K, Zarhrate M, Bondet V, Nguyen V, Akroun F, Nitschké P, Guerrera IC, Bole C, Izmiryan[...]

A practical inflammatory blood-cell marker for cardiovascular risk stratification in psoriasis: Development of the Platelet-Leukocyte Adjusted Cardiovascular (PLAC) score

Cortes JA, Aflatooni S, Ure A, Palma G, Johnsen N, Smart K, Nong Y, Armstrong AW. A practical inflammatory blood-cell marker for cardiovascular risk stratification[...]

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials

Stein Gold L, Armstrong AW, Soung J, Vender RB, González Cantero Á, Hoffmann M, Guenthner ST, Hong HC, Murrell DF, Song EJ, Kircik L, Augustin[...]